Abstract: The present invention declares a pharmaceutical extract, composition that has effect to treat drug addiction, and its preparation method and quality control method. This extract is extracted from Radix Stephaniae Epigaeae. Starting medicine material of said composition is Radix Ginseng, Radix Astragali, Rhizoma Corydalis, Radix Angelicae Sinensis and Radix Ophiopogonis; and said composition also can prepared by ethanol extract of Radix Ginseng, ethanol extract of Radix Angelicae Sinensis, total alkaloids of Radix Stephaniae Epigaeae, water extract of Radix Astragali and water extract of Radix Ophiopogonis. Quality control method of said pharmaceutical composition includes one of or several of identifications and content determinations. The present invention also declares the use of said pharmaceutical extract, composition in the preparation of a medicine to treat drug addiction.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
January 29, 2013
Assignees:
Shanxi Yabad Pharmaceutical Group Corp., Institute of Basic Medical Sciences, Academy of Military Medical Sciences
Abstract: Provided are a hepatopoietin PCn (HPPCn) and its homologous proteins, which can promote hepatocyte proliferation in vitro, promote liver regeneration in vivo, inhibit the growth of tumor cells and promote the apoptosis of tumor cells. The hepatopoietin PCn (HPPCn) and its homologous proteins are useful for the treatment of acute and chronic liver injury, or the treatment of liver fibrosis.
Type:
Grant
Filed:
December 21, 2007
Date of Patent:
January 29, 2013
Assignee:
Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
Abstract: The present invention relates to an acyclic nucleoside phosphonate derivative and medical uses thereof. Specifically, the present invention relates to an acyclic nucleoside phosphonate derivative of Formula I having strong potency against viruses, such as hepatitis B virus, and low cytotoxicity, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, wherein R1 is H or methyl; each R2 is independently —R3 or —OR3, each R3 is independently C1-C8 alkyl, C3-C8 cycloalkyl. The present invention further relates to a process for preparing the compounds of Formula I, a pharmaceutical composition comprising the compound, and the medical uses of the compound. The acyclic nucleoside phosphonate derivative of the present invention has activity against virus such as hepatitis B virus and good in vivo behavioral traits.
Type:
Application
Filed:
June 21, 2010
Publication date:
December 20, 2012
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical sciences P.L.A. China
Inventors:
Bohua Zhong, Xinhua He, Yongguang Wang, He Liu
Abstract: The present invention relates to a pharmaceutical composition for combating a thrombotic disease and a method for making the same and a use thereof. The pharmaceutical composition mainly comprises timosaponin AIII and timosaponin BII, and optionally pharmaceutically acceptable excipients, characterized in that the amount of timosaponin AIII is greater than or equal to the amount of timosaponin BII. The present invention further relates to a use of timosaponin AIII and timosaponin BII in manufacturing a medicament or product for the prophylaxis or to treatment of a thrombotic disease. The present pharmaceutical composition can not only bring about effects of prophylaxis or treatment of a thrombotic disease, but also alleviate blood bleeding or bleeding tendency in patients.
Type:
Application
Filed:
September 7, 2009
Publication date:
December 13, 2012
Applicant:
INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES ,PLA
Abstract: The present invention relates to a new amine compound or a pharmaceutically acceptable salt thereof, wherein the definitions of X, R1, R2 and n are given in the description, to a pharmaceutical composition containing the compound as active ingredient, and to use of the amine compound or its pharmaceutically acceptable salt for the manufacture of an anti-depressent drug.
Type:
Grant
Filed:
June 23, 2009
Date of Patent:
November 27, 2012
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Bohua Zhong, Youzhi Zhang, Yanping Zhang, Rui Xue, Xinhua He, Yunfeng Li, Hongxia Chen, Nan Zhao, Meiying Li
Abstract: The present invention relates to multi-substituted m-diarylanilines or pharmaceutically acceptable salts thereof, wherein X, R1-R7 are as defined in the claims, their preparation process, pharmaceutical compositions comprising them and their use for the manufacture of a medicament for anti-HIV.
Type:
Grant
Filed:
October 7, 2008
Date of Patent:
November 13, 2012
Assignees:
Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences P.L.A. China
Inventors:
Lan Xie, Bingjie Qin, Kuo-Hsiung Lee, Shibo Jiang, Hong Lu
Abstract: The present invention relates to compounds represented by formula (I), or isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof: in which each substituent of formula (I) is as defined in the specification. The present invention also relates to preparation methods of compounds represented by formula (I), a pharmaceutical composition comprising compounds represented by formula (I) and usage of compounds represented by formula (I) for treating chronic neurodegenerative diseases such as Alzheimer's disease and other diseases induced by aggregation or deposition of ?-amyloid peptide.
Type:
Grant
Filed:
February 5, 2007
Date of Patent:
September 18, 2012
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Song Li, Guochao Liao, Junhai Xiao, Aihua Nie, Lili Wang, Wu Zhong, Zhibing Zheng
Abstract: This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.
Type:
Grant
Filed:
September 3, 2003
Date of Patent:
July 3, 2012
Assignee:
Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
Abstract: Disclosed are dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof. Specifically, the compounds described herein in general formula (I), or their isomers, pharmaceutically acceptable salts or hydrates are provided, wherein each variable has the meaning as defined in the description. Also provided are a process for preparing the compounds of the general formula (I), the use of the compounds, an isomer thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof as a medicament, in particular as a medicament for the treatment and/or prevention of Hepatitis B.
Type:
Application
Filed:
May 27, 2010
Publication date:
June 14, 2012
Applicant:
INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A.
Abstract: The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.
Type:
Application
Filed:
March 29, 2010
Publication date:
May 17, 2012
Applicant:
INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A.CHINA
Abstract: The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.
Type:
Application
Filed:
September 28, 2009
Publication date:
March 1, 2012
Applicant:
INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
Inventors:
Lan Xie, Xingtao Tian, Kuo-Hsiung Lee, Shibo Jiang, Hong Lu
Abstract: Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.
Type:
Grant
Filed:
December 11, 2007
Date of Patent:
January 24, 2012
Assignees:
Institute of Radiation Medicine Academy of Military Medical Science, Beijing Sanly Sci-Tech Develop Inc. Ltd.
Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.
Type:
Application
Filed:
September 28, 2009
Publication date:
December 29, 2011
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Science, P.L.A
Inventors:
Jin Li, Rifang Yang, Rui Song, Hui Zhu, Ning Wu, Liuhong Yun, Ruibin Su, Rusheng Zhao
Abstract: The present invention provides a selective M4 receptor antagonist, levorotatory demethylated phencynonate or its nontoxic pharmaceutically acceptable salt, a pharmaceutical composition comprising this compound, and a use thereof in the manufacture of a medicament for the treatment of motion dysfunction, such as, tremor, rigor and the like caused by Parkinson's disease (PD).
Type:
Application
Filed:
November 7, 2007
Publication date:
December 15, 2011
Applicant:
INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A.CHINA
Inventors:
Bohua Zhong, Jianquan Zheng, Liyun Wang, He Liu, Lanfu Chen, Keliang Liu
Abstract: The present invention relates to substituted pyridazinylamine derivatives of the formula I or pharmaceutically acceptable salts or hydrates thereof, wherein the substituents are defined as in the description, their preparation process, pharmaceutical compositions comprising them, and uses of the said compounds as picorna virus inhibitors for prevention and/or treatment of diseases caused by picorna viruses.
Type:
Grant
Filed:
November 14, 2005
Date of Patent:
December 13, 2011
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China of Beijing
Inventors:
Song Li, Chunlai Mi, Zhibing Zheng, Guoming Zhao, Xinbo Zhou, Zehui Gong
Abstract: The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.
Type:
Grant
Filed:
August 15, 2006
Date of Patent:
November 8, 2011
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.C. China
Abstract: The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications.
Type:
Grant
Filed:
July 20, 2005
Date of Patent:
October 18, 2011
Assignee:
Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
Abstract: The invention disclosed the use of timosaponin BII in the preparation of a medicament or product for the prevention and treatment of stroke. The experiments prove that timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury of cerebral ischemia.
Type:
Grant
Filed:
April 21, 2005
Date of Patent:
August 16, 2011
Assignee:
Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
Inventors:
Baiping Ma, Quiping Xu, Yang Zhao, Chengqi Xiong, Dawei Tan
Abstract: The present invention relates to a new amine compound or a pharmaceutically acceptable salt thereof, wherein the definitions of X, R1, R2 and n are given in the description, to a pharmaceutical composition containing the compound as active ingredient, and to use of the amine compound or its pharmaceutically acceptable salt for the manufacture of an anti-depressent drug.
Type:
Application
Filed:
June 23, 2009
Publication date:
July 21, 2011
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Bohua Zhong, Youzhi Zhang, Yangping Zhang, Rui Xue, Xinhua He, Yunfeng Li, Hongxia Chen, Nan Zhao, Melying Li
Abstract: Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2) significant therapeutic effect, with remarkable proliferation inhibiting and pro-apoptotic effects in tumor cells; (3) a broad-spectrum anticancer activity; (4) suitable to be used in combination with antimetabolites, to enhance the effects and meanwhile lower the toxicity, and also to reduce multi-drug resistance; (5) convenient and safe administration, the main route being oral.
Type:
Grant
Filed:
February 25, 2008
Date of Patent:
July 19, 2011
Assignee:
Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
Inventors:
Pingkun Zhou, Yuqian Yan, Lin Wang, Jianli Sui